References
- Mason A S, Forrest I, Forrest F. Adherence to maintenance therapy and rehopsitalization. Dis Nerv Syst 1963; 24: 103–104
- Raskin M, Dyson W L, Adams M E. Depot neuroleptic therapy: clinical considerations. Can J Psyuchiatry 1995; 40: S5–S11
- Johnson D AW, Pasterski G, Ludlow J M. The discontinuation of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983; 67: 339–52
- Kasper J A, Hoge S K, Feucht-Haviar T, et al. Prospective study of patients' refusal of antipsychotic medication under a physician discretion review procedure. Am J Psychiatry 1997; 154: 483–9
- Bourin M, Venisse J L, Lecuyer F. Résultats d'une enquéte sur l'utilisation en psychiatrie des neuroleptiques à action prolongée. Encéphale 1990; 16: 363–9
- Gaebel W. Towards the improvement of compliance: the significance of psychoeducation and new antipsychotics drugs. Int Clin Psychopharmacol 1997; 12: S37–S42
- Lin I F, Spiga R, Fortsch W. Insight and adherence to medication in chronic schizophrenics. J Clin Psychiatry 1979; 40: 430–2
- McEvoy J P, Appelbaum P S, Apperson I J. Why must some schizophrenic patients be involuntarily committed? the role of insight. Compr Psychiatry 1989; 30: 13–17
- Buchanan R W, Carpenter W T. Targeted maintenance treatment in schizophrenia. CNS Drugs 1996; 5: 240–5
- Bartel S J, Drake R E. Depressive symptoms in schizophrenia: comprehensive differential diagnosis. Compr Psychiatry 1988; 29: 467–83
- Carpentier W T, Jr, Heinrichs D W, Wagman A ML. Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145: 578–83
- Lindström L H. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand 1994; 89(suppl 380)74–6
- Kane J, Aguglia E, Altamura A C, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998; 8: 55–66